Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Inclusion Criteria:

• Histologically or cytologically confirmed high grade serous or high gradeendometrioid ovarian, primary peritoneal, and/or fallopian tube cancer that isrecurrent.

• Participants whose tumor carries germline or somatic deleterious or suspecteddeleterious mutations in the genes BRCA1 (Breast Cancer gene 1) and BRCA2 (BreastCancer gene 2), and/or tumors with positive HRD status. The presence of any of thesemutations and/or the homologous recombination deficiency (HRD) status will bedetermined according to routinely used local standard of care tests. Results must beavailable before screening.

• Radiologically confirmed/documented disease progression while on Poly (ADP-ribose)polymerase (PARP) inhibitors therapy in either first or second-line maintenancesetting (only 1 line of PARPi maintenance is allowed with or without bevacizumab).Note: Documentation of disease progression must be within 28 days of last PARPi dosetaken. Surgical salvage intervention and/or focal ablative therapies are allowed, (further disease progression after these interventions must be documented), ANDClinically benefited from PARPi maintenance prior to documented progression, asdefined by at least 6 months of treatment duration with no progressive diseaseobserved, AND either, Progression on first-line maintenance PARPi: Participants areallowed maximum 1 additional line of platinum-based chemotherapy before study entry. (note: treatment-free interval on platinum rechallenge must be >6 months, withdocumented disease progression prior to study entry).

OR Progression on second-line maintenance PARPi: Participants are not allowed any additional systemic anticancer treatments before study entry (that is PARPi is the last treatment before study entry)

• Measurable disease per RECIST v1.1, as assessed by Investigator.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a lifeexpectancy of at least 6 months.

• Other Protocol defined inclusion criteria could apply.

Exclusion Criteria:

• Primary platinum-refractory disease defined as disease progression during primaryplatinum-based chemotherapy or platinum-resistant disease defined as diseaseprogression within 6 months of the last platinum administration in the second-linesetting.

• History of additional malignancy within 3 years before the date of enrollment.

• Known brain metastases, unless clinically stable, that is without evidence ofprogression by imaging for at least 4 weeks prior to the first dose of studyintervention, no evidence of new brain metastases, and on a stable or decreasingdose of ≤ 10 mg of prednisone (or equivalent) or without corticosteroids for atleast 14 days prior to study intervention administration.

• Active and/or uncontrolled infection.

• History of known hypersensitivity to the active substances or to any excipients (e.g. polysorbate 80) of the study interventions.

• Organ transplantation, including allogenic stem cell transplant.

• Other Protocol defined exclusion criteria could apply.